AA
ABUS icon

ALPS Advisors’s Arbutus Biopharma ABUS Stock Holding History

ALPS Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-107,107
Closed -$325K – 995
2023
Q1 		$325K Buy
107,107
+877
+0.8% +$2.47K ﹤0.01% 781
2022
Q4 		$248K Buy
106,230
+24,352
+30% +$58.3K ﹤0.01% 966
2022
Q3 		$156K Sell
81,878
-6,346
-7% -$14.9K ﹤0.01% 1019
2022
Q2 		$239K Sell
88,224
-64,538
-42% -$165K ﹤0.01% 961
2022
Q1 		$455K Sell
152,762
-3,784
-2% -$11.6K ﹤0.01% 444
2021
Q4 		$609K Buy
+156,546
New +$608K 0.01% 465
2019
Q2 		– Sell
-134,053
Closed -$480K – 878
2019
Q1 		$480K Buy
134,053
+6,016
+5% +$23.1K ﹤0.01% 535
2018
Q4 		$490K Buy
+128,037
New +$631K ﹤0.01% 485

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return